Trials / Terminated
TerminatedNCT03883386
Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- University of Michigan · Academic / Other
- Sex
- All
- Age
- 12 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Loratadine | 10 mg in a capsule |
| DRUG | Placebo | Administered via capsule |
Timeline
- Start date
- 2019-06-24
- Primary completion
- 2019-10-18
- Completion
- 2019-10-18
- First posted
- 2019-03-20
- Last updated
- 2020-10-22
- Results posted
- 2020-10-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03883386. Inclusion in this directory is not an endorsement.